pharma · Breast Cancer · Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
Pierre Fabre Medicament
Pierre Fabre Medicament trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
LAVAUR, FR HQ
176 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- LAVAUR, FR
- Employees
- 176
- Programs
- 8
- Drugs
- 13
- Patents
- 0
Pierre Fabre Medicament clinical trials
Registry index of 8 ClinicalTrials.gov studies linked to Pierre Fabre Medicament programs — each row shows trial ID, program name, phase, status, and indication.
Pierre Fabre Medicament trial registry — 8 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Pierre Fabre Medicament.
Trial registry
-
CTIS ↗ -
CTIS ↗ - 2023-510203-21-00CTIS ↗
F60087CI101
locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-516623-14-00CTIS ↗
EBVALLO
EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)
-
CT.gov ↗